- Home
- NTLA vs UAN Comparison
NTLA vs UAN Comparison
Compare NTLA & UAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- UAN
- Stock Information
- Founded
- NTLA 2014
- UAN 2007
- Country
- NTLA United States
- UAN United States
- Employees
- NTLA N/A
- UAN N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- UAN Agricultural Chemicals
- Sector
- NTLA Health Care
- UAN Industrials
- Exchange
- NTLA Nasdaq
- UAN Nasdaq
- Market Cap
- NTLA 959.4M
- UAN 793.5M
- IPO Year
- NTLA 2016
- UAN 2011
- Fundamental
- Price
- NTLA $9.53
- UAN $81.47
- Analyst Decision
- NTLA Buy
- UAN
- Analyst Count
- NTLA 18
- UAN 0
- Target Price
- NTLA $50.53
- UAN N/A
- AVG Volume (30 Days)
- NTLA 3.2M
- UAN 36.3K
- Earning Date
- NTLA 02-20-2025
- UAN 02-18-2025
- Dividend Yield
- NTLA N/A
- UAN 8.19%
- EPS Growth
- NTLA N/A
- UAN N/A
- EPS
- NTLA N/A
- UAN 4.97
- Revenue
- NTLA $43,086,000.00
- UAN $527,388,000.00
- Revenue This Year
- NTLA $50.68
- UAN N/A
- Revenue Next Year
- NTLA N/A
- UAN N/A
- P/E Ratio
- NTLA N/A
- UAN $16.26
- Revenue Growth
- NTLA N/A
- UAN N/A
- 52 Week Low
- NTLA $9.25
- UAN $61.62
- 52 Week High
- NTLA $34.87
- UAN $88.94
- Technical
- Relative Strength Index (RSI)
- NTLA 36.07
- UAN 57.61
- Support Level
- NTLA $9.93
- UAN $80.28
- Resistance Level
- NTLA $10.73
- UAN $83.76
- Average True Range (ATR)
- NTLA 0.66
- UAN 2.29
- MACD
- NTLA 0.08
- UAN -0.24
- Stochastic Oscillator
- NTLA 13.12
- UAN 29.49
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.